-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Economic Daily-China Economic Net
According to statistics, there are about 70 million cases of hepatitis B virus carriers in my country, including about 20 million to 30 million cases of chronic hepatitis B patients.
What are the ways of transmission of hepatitis B
What are the ways of transmission of hepatitis BChronic hepatitis B is a chronic inflammatory disease of the liver caused by chronic hepatitis B virus (HBV) persistent infection.
In my country, mother-to-child transmission is the main mode of transmission of chronic hepatitis B, accounting for 30% to 50%.
HBV does not spread through the respiratory and digestive tracts.
How to prevent hepatitis B
How to prevent hepatitis BProtect susceptible people.
Manage the source of infection.
Cut off the route of transmission.
How to treat hepatitis B
How to treat hepatitis BFor hepatitis B, there is currently no cure, but drugs can control virus replication, delay the progression of the disease, improve the quality of life of patients, and prolong their survival time.
During hepatitis B treatment, the medication cycle is longer, generally at least 2 to 3 years, or even for life.
Tenofovir, a traditional treatment for hepatitis B, can cause gastrointestinal reactions, osteoporosis, and renal tubular damage.
At the 2021 Asia-Pacific Association of Liver Diseases Annual Meeting (2021APASL), researchers from Southern Medical University Nanfang Hospital and Hausen Pharmaceuticals (the main body of Hansen Pharmaceuticals) jointly published a large-scale phase III clinical study of the drug in Chinese patients with chronic hepatitis B 48 weeks results.
Considering that patients with hepatitis B need long-term medication, imitenofovir can help patients with hepatitis B reduce the side effects of the drug while achieving a curative effect equivalent to that of tenofovir disoproxil (TDF).